WXXWY - Arcus Biosciences WuXi Biologics expands antibodies development pact

Arcus Biosciences ([[RCUS]] +2.6%) has expanded its existing strategic relationship with WuXi Biologics ([[WXXWY]] -65.6%) to discover anti-CD39 antibodies using the latter’s proprietary technology. It is the fourth antibody development program for which the two firms have collaborated.Arcus will gain exclusive worldwide rights to anti-CD39 antibodies discovered under the partnership and handle all their further development and commercialization activities.Arcus currently has Etrumadenant (AB928), AB680, Domvanalimab (AB154) and Zimberelimab (AB122) molecules in the clinical development stage.Financial terms of the agreement were not disclosed, and the development of any anti-CD39 antibodies from the collaboration is not expected to materially impact Arcus’s financial position over the current cash runway.

For further details see:

Arcus Biosciences, WuXi Biologics expands antibodies development pact